Shyuan T Ngo1,2,3,4,5, Ruben P A van Eijk6,7, V Chachay8, Leonard H van den Berg6, Pamela A McCombe3,4,5, Robert D Henderson2,3,4,5, Frederik J Steyn1,3,4,5. 1. Australian Institute for Bioengineering and Nanotechnology, The University of Queensland , Brisbane , Australia. 2. Queensland Brain Institute, The University of Queensland , Brisbane , Australia. 3. Centre for Clinical Research, The University of Queensland , Brisbane , Australia. 4. Department of Neurology, Royal Brisbane and Women's Hospital , Brisbane , Australia. 5. Wesley Medical Research, The Wesley Hospital , Brisbane , Australia. 6. Department of Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht , Utrecht , The Netherlands. 7. Biostatistics & Research Support, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht , Utrecht , The Netherlands , and. 8. School of Human Movement and Nutrition Sciences, The University of Queensland , Brisbane , Australia.
Abstract
Objective: Weight loss in amyotrophic lateral sclerosis (ALS) is associated with faster disease progression and shorter survival. It has different possible causes, including loss of appetite. Our objective is to determine the prevalence and impact of loss of appetite on change in body weight and composition in patients with ALS. Methods: We conducted a prospective case-control study, comparing demographic, clinical, appetite and prognostic features between 62 patients with ALS and 45 healthy non-neurodegenerative disease (NND) controls. To determine the impact of loss of appetite on weight throughout disease course, we conducted serial assessments at ∼three to four-month intervals. Results: Loss of appetite is more prevalent in patients with ALS than NND controls (29 vs. 11.1%, odds ratio = 3.27 (1.1-9.6); p < 0.01). In patients with ALS, loss of appetite is associated with greater weight loss and greater loss of fat mass. Appetite scores in patients with ALS worsens as disease progresses and are correlated with worsening ALS Functional Rating Scale-Revised scores. Conclusion: We confirm that loss of appetite is prevalent in patients with ALS and is significantly associated with weight loss and loss of fat mass. Appetite worsens with disease progression. Identification and early interventions to address loss of appetite in patients with ALS may prevent or slow weight loss; this could improve disease outcome.
Objective: Weight loss in amyotrophic lateral sclerosis (ALS) is associated with faster disease progression and shorter survival. It has different possible causes, including loss of appetite. Our objective is to determine the prevalence and impact of loss of appetite on change in body weight and composition in patients with ALS. Methods: We conducted a prospective case-control study, comparing demographic, clinical, appetite and prognostic features between 62 patients with ALS and 45 healthy non-neurodegenerative disease (NND) controls. To determine the impact of loss of appetite on weight throughout disease course, we conducted serial assessments at ∼three to four-month intervals. Results:Loss of appetite is more prevalent in patients with ALS than NND controls (29 vs. 11.1%, odds ratio = 3.27 (1.1-9.6); p < 0.01). In patients with ALS, loss of appetite is associated with greater weight loss and greater loss of fat mass. Appetite scores in patients with ALS worsens as disease progresses and are correlated with worsening ALS Functional Rating Scale-Revised scores. Conclusion: We confirm that loss of appetite is prevalent in patients with ALS and is significantly associated with weight loss and loss of fat mass. Appetite worsens with disease progression. Identification and early interventions to address loss of appetite in patients with ALS may prevent or slow weight loss; this could improve disease outcome.
Authors: Ikjae Lee; Mohamed Kazamel; Tarrant McPherson; Jeremy McAdam; Marcas Bamman; Amy Amara; Daniel L Smith; Peter H King Journal: PLoS One Date: 2021-05-06 Impact factor: 3.240
Authors: B Kuraszkiewicz; H Goszczyńska; T Podsiadły-Marczykowska; M Piotrkiewicz; P Andersen; M Gromicho; J Grosskreutz; M Kuźma-Kozakiewicz; S Petri; B Stubbendorf; K Szacka; H Uysal; M de Carvalho Journal: Front Neurosci Date: 2020-05-26 Impact factor: 4.677